Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Tuesday, SpringWorks Therapeutics (NASDAQ:SWTX), a $3 billion market cap biotech company with impressive 93% gross margins, received a reiterated Overweight rating and a $63.00 price target from Barclays (LON:BARC). The focus is on the potential EU approval of the company’s drug Ogsiveo for desmoid tumors, which could pave the way for a significant corporate development.
The Committee for Medicinal Products for Human Use (CHMP) included Ogsiveo on its agenda for a meeting that took place today at 10 am ET. A positive outcome from this meeting could result in a green light from the European Union, which is seen as a crucial step for SpringWorks. According to InvestingPro, the company maintains strong financial health with more cash than debt on its balance sheet.
Barclays analyst highlighted that a favorable opinion from the CHMP could de-risk the drug’s path to market in the EU and may also influence the dynamics of a possible acquisition of SpringWorks by Merck (NSE:PROR) KGaA. The acquisition has been under consideration, as indicated by Merck KGaA on February 10, 2025, with the stipulation that certain critical conditions still needed to be met.
The CHMP’s decision on Ogsiveo is eagerly anticipated, as EU approval is deemed a key catalyst for the completion of the potential acquisition. The outcome of today’s meeting could therefore have significant implications for SpringWorks’ future, especially in relation to its relationship with Merck KGaA.
In other recent news, SpringWorks Therapeutics has received FDA approval for its drug GOMEKLI, intended for treating neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. This approval is particularly notable as it includes a rare pediatric disease priority review voucher, potentially valued at around $100 million. The approval was based on positive Phase 2b ReNeu trial results, showing significant tumor volume reductions and improvements in pain and quality of life for both adults and children. Additionally, TD Cowen analysts have raised their price target for SpringWorks shares to $66, maintaining a "Buy" rating, following the positive reception of GOMEKLI. Analysts also highlighted the ongoing acquisition discussions between Merck KGaA and SpringWorks Therapeutics, suggesting a potential deal valued between $6 billion and $7.5 billion. Merck KGaA has confirmed that they are in advanced talks for this acquisition, although no legally binding agreement has been reached. SpringWorks has also launched Ogsiveo, a treatment for desmoid tumors, and is awaiting regulatory decisions on mirdametinib, another treatment for NF1. These developments reflect SpringWorks’ growing influence in the biopharmaceutical sector, particularly in rare disease treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.